Deals review
- Deals review
- Deal details
SEQUELLA, INC. AND SANKYO CO., LTD. SIGN WORLDWIDE LICENSING AGREEMENT TO DEVELOP AND MARKET PROMISING NEW ANTI TUBERCULOSIS COMPOUNDS
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Subscribe now for instant access to the benefits Pharmalicensing Intelligence has to offer. Find out more.
Related deals
Peregrine gains license for novel new anti-cancer compounds
Roche licenses compounds to treat Alzheimer's
Sankyo and Fujisawa Agree to Discontinue Business Arrangements on Sankyo's Antifungal CS-758
Sankyo gains rights to cholesterol lowering agent
Related categories
- Therapeutic target
- Infectious diseases
- Diseases
- Tuberculosis
- Industry sector
- Pharmaceutical
- Prescription
More deals
Latest deals
- Biovator and BASF sign technology development agreement
- Agfa HealthCare signs four-year agreement with Chinese partners for distribution of radiography solutions, potentially worth 500 million US dollar
- Omnicare Announces Acquisition of Continuing Care Rx
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- GreenVax Selects Xcellerex XDR Single-Use Bioreactors for New Vaccine and Biotherapeutics Program
Most viewed deals
- Recommended acquisition of Acambis plc ("Acambis") by Sanofi Pasteur Holding ("Sanofi Pasteur") by way of scheme of arrangement Posting of Scheme Document
- Omnicare Announces Acquisition of Continuing Care Rx
- Bayer CropScience and Janssen PMP conclude research agreement:
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- Biovator and BASF sign technology development agreement
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us